Although polymorphonuclear neutrophils (PMN) are well recognized for playing important roles in infl ammation in sickle cell disease (SCD), direct evidence linking myeloperoxidase (MPO) to impaired vascular endothelial cell (EC) function in SCD remains lacking. Over the last 25 years, only a handful of studies have been published suggesting that MPO may be involved. One of the fi rst reports, published in 1986, showed that vaso-occlusive crises increased PMN stickiness, an index of activation, in SCD patients ( 1 ). In 1993, plasma levels of MPO and C3d were reported to be higher in SCD patients than in controls, and these biomarkers inversely correlated with red cell hemoglobin ( 2 ). In 1996, PMN were shown to interact directly with the sickle red blood cell (RBC), and this interaction notably enhanced PMN activation ( 3 ). Later in 2002, it was reported that activated PMN increased sickle RBC retention in isolated rat lungs ( 4 ) and that MPO and 3-nitrotyrosine colocalized in sections of lungs from patients who died from complications associated with SCD ( 5 ). Evidence that stress increases MPO in SCD comes from studies showing that exercise induced a dual increase in plasma MPO and percentage of sickled cells in SCD patients ( 6 ). Finally, evidence linking the coagulation pathway to infl ammation in sickle cell anemia comes from studies showing that inhibiting tissue factor decreased MPO in the lungs of SCD mice ( 7 ). Although these reports and others ( 8-10 ) provide strong support for the idea that PMN activation and MPO play important roles in SCD, 
for human; Minneapolis, MN). Plasma MPO protein levels were quantifi ed using ELISA kits from Hycult Biotech, Inc. (HK210 for mouse and HK324 for human; Plymouth Meeting, PA). All assays were performed in duplicate.
Immunofl uorescence studies
Thoracic aortas were surgically removed and rinsed free of blood elements with ice-cold PBS. Livers were isolated from perfused SCD mice. The aortas and livers were fi xed in 10% PBSformalin, imbedded in paraffi n, and sectioned. The slides were deparaffi nized using a descending alcohol-row. After a single wash with PBS (5 min), the slides were incubated with primary antibodies against MPO (0.5 mg/ml), 3-ClTyr (1:50 dilution), 3-NO 2 Tyr or XO/XDH for 30 min at 37°C. Aortic sections were stained for anti-CD45 and anti-CD64 to detect leukocytes and PMN, respectively. The slides were washed with PBS (2 × 5 min) followed by incubation with the appropriate secondary antibody labeled with Alexa 488 (Invitrogen, Carlsbad, CA) for 30 min at 37°C. Finally, the slides were washed with PBS (2 × 5 min) followed by a 3 min incubation with To-Pro3 (1 µg/ml, Invitrogen), and then sealed with an aqueous mounting media and stored at Ϫ 20°C until analysis by confocal microscopy.
Vasodilatation
Mice were anesthetized and then euthanized by exsanguination. The facialis arteries were isolated by microdissection, cannulated, and pressurized. Physiological responses to increasing concentrations of acetylcholine (ACh) were determined in the absence and presence of L-nitroargininemethylester (L-NAME) by videomicroscopy as previously described ( 13 ) .
Effects of KYC on MPO-mediated oxidation of EC protein
MPO (10 ng/ml) and H 2 O 2 (20 µM) were added to confl uent human umbilical vein endothelial cell (HUVEC) cultures ± KYC (25 µM) in HBSS for 15 min at 37°C. Excess buffer was removed, cells were lysed, and cell proteins were separated by SDS-PAGE. EC proteins were transferred to nitrocellulose membranes, and membranes were immunoblotted for 3-ClTyr and endothelial nitric oxide synthase (eNOS) as described ( 14 ) .
Plasma alanine transaminase measurements
Alanine transaminase (ALT) activity in plasma was measured using EnzyChrom™ Alanine Transaminase Assay Kit (BioAssay Systems, Cat# EALT-100; Hayward, CA) following the manufacturer's protocol. Briefl y, 20 µl of plasma was mixed with lactate dehydrogenase (LDH), the cosubstrate, NADH, in assay buffer and then incubated at room temperature. Water was substituted for plasma to generate NADH standards while plasma and NADH were both replaced with water to generate reagent blanks. Absorbance at 340 nm was measured after incubation at 5 min and 10 min. ALT activity was calculated per manufacturer's equation: ALT = 381 × [(ODsample,5min Ϫ ODsample,10min) Ϫ (ODstd,5min Ϫ ODstd,10min)] / (ODstd,5min Ϫ ODblank,5min) (U/l). All assays were performed in duplicate.
Liver immunofl uorescence studies and 3-ClTyr and 3-NO 2 Tyr immunoblots
To assess the effects of SCD and KYC on oxidative stress in liver, livers were perfused in situ and then removed. One lobe was fi xed in paraffi n, and sections were cut for immunofl uorescence studies. The other lobe was homogenized, and the homogenates were centrifuged to remove cell debris. The liver proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. The membranes were immunoblotted for MPO, XO/XDH, 3-ClTyr, and 3-NO 2 Tyr as described ( 14 ) . direct proof of MPO increasing oxidative stress, vascular EC dysfunction, and liver injury in SCD remains lacking.
In the present report, control (AA) and SCD mice were treated with N-acetyl-lysyltyrosylcysteine-amide (KYC), a novel tripeptide inhibitor of MPO that dose-dependently inhibits MPO HOCl production, MPO-mediated LDL oxidation, and MPO-dependent EC injury and death ( 11 ) . Our studies show that KYC decreases soluble L-selectin (sL-selectin), oxidative stress, and liver injury and that it improves vascular EC function in SCD mice. 
MATERIALS AND METHODS

Humans
Mice
Both male and female Berkeley SCD and AA mice were used for the studies. The genetics and hematological characteristics of MCW Berkeley SCD and AA mice have been described previously ( 12 ) . All of the mice used for the studies were approximately 12-14 weeks old. Mice were housed in sterile autoclavable microisolation cages. Standard mouse chow and water were provided ad libitum. SCD and AA mice were treated with KYC (0.3 mg/kg/day via intraperitioneal or subcutaneous injection) or with an injection of an equal volume of PBS for 3 weeks. All research involving the mice was conducted in conformity with PHS policy. The Institutional Animal Care and Use Committee (IACUC) of the MCW approved all protocols.
Materials
The MPO antibody (ab65871) was from Abcam (Cambridge, MA). The 3-ClTyr antibody (HP5002) was from Cell Science (Canton, MA). The XO/XDH antibody (Cat# MS-474-P) was from NeoMarkers (Freemont, CA). The 3-NO 2 Tyr antibody (Cat# 10189540) was from Cayman Chemical (Ann Arbor, MI). The ␤ -actin antibody, a loading control, was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-CD45 and anti-CD64 antibodies were from Santa Cruz Biotechnology. All other chemicals and reagents were from Sigma-Aldrich (St. Louis, MO).
Peptide synthesis
KYC was synthesized using Fmoc [N-(9-fl uorenyl)methoxycarbonyl] chemistry and purifi ed by the Protein, Nucleic Acid Core Laboratory of the Medical College of Wisconsin or was made by Biomatik USA, LLC (Wilmington, DE). Purity was confi rmed by HPLC analysis (Agilent, Model 1200) using a C-18 column (2.3 × 150 mm) and a CH 3 CN gradient over 30 min (5-50%, 0.1% TFA, fl ow rate 0.22 ml/min). Structural authenticity of the tripeptide was confi rmed by matrix-assisted laser desorption ionization time-of-fl ight mass spectrometry.
the aortic wall as a means of increasing vascular oxidative stress ( Fig. 2C ) .
Although KYC treatments slightly decreased eNOSdependent vasodilatation in AA mice, the differences between means were not statistically signifi cant ( Fig. 3A ) . KYC increased vasodilatation in SCD mice (black triangle for KYC group and black square for PBS group, Fig. 3B , P < 0.001). L-NAME inhibited vasodilatation of vessels isolated from the KYC treated group (white triangle) ( Fig. 3B , P < 0.001), suggesting that the mechanism by which KYC improved vasodilatation was, for the most part, eNOSdependent. Overall, KYC treatments improved ACh-induced vasodilatation by more than 2-fold ( Fig. 3C ).
Plasma malondialdehyde
Plasma malondialdehyde (MDA), a highly reactive di-aldehyde generated from free radical oxidation of polyunsaturated fatty acids, was measured using the TBARS Assay Kit from Cayman Chemical, Inc. (Cat# 10009055; Ann Arbor, MI) following the manufacturer's published protocol with some modifi cations. Briefl y, BHT was added to plasma samples at a fi nal concentration of 0.05%. The BHT-treated samples were incubated with TBA reagent at 100°C for 1 h. The reaction was halted by cooling the mixture on ice. MDA-TBA adducts in the samples and standards were extracted into n-butanol. MDA levels were calculated by comparing the fl uorescence ( Ex / Em = 530/550 nm) intensity in the samples to concentration-dependent increases in fl uorescence in external MDA standards.
Statistical analysis
Statistical analysis was by the Student t -test for comparisons between two groups. Vasodilatation data were analyzed using ANOVA and Boniferroni analysis for post-hoc comparisons. All data were presented as mean ± SEM unless otherwise indicated.
RESULTS
SCD patients have higher plasma MPO than controls ( Fig. 1A , left) . SCD mice have higher plasma MPO than AA mice. KYC had no effect on plasma MPO in SCD mice ( Fig. 1A , right) . SCD patients have higher plasma sL-selectin than controls ( Fig. 1B , left) . SCD mice have higher sLselectin than AA mice. KYC decreased sL-selectin in SCD mice to the levels in AA mice. As sL-selectin is a biomarker of leukocyte activation and interactions with the vessel wall ( 10 ), these data suggest that KYC treatments decrease leukocyte activation and interactions with the vessel wall.
Low levels of MPO (green, Fig. 2A , far left) and 3-ClTyr (green, Fig. 2B , far left) were observed in sections of thoracic aortas isolated from PBS-treated AA mice. KYC treatments reduced immunostaining for MPO ( Fig. 2A , second left) and 3-ClTyr ( Fig. 2B , second left) below the levels observed in sections of aortas isolated from PBS-treated AA mice.
In contrast to AA mice, high levels of MPO (green, Fig.  2A , middle right) and 3-ClTyr (green, Fig. 2B , middle right) were observed in sections of thoracic aortas isolated from PBS-treated SCD mice. MPO and 3-ClTyr staining appeared as diffuse punctuate spots throughout the smooth muscle cell layers in thoracic aortas isolated from PBStreated SCD mice. In some images, intense MPO and 3-ClTyr staining was observed on the endothelium of aortas isolated from PBS-treated SCD mice. Control studies indicate that the adventitia have increased nonspecifi c staining for MPO and 3-ClTyr (data not shown). KYC reduced immunostaining for MPO ( Fig. 2A , middle right) and 3-ClTyr ( Fig. 2B , middle right) below that observed in sections of thoracic aortas isolated from PBS-treated SCD mice. H&E sections showed no differences in aortic structure. Few if any cells in the aortic sections stained positive for CD45 or CD64 in thoracic aorta from AA and SCD mice regardless of treatments (data not shown), confi rming a lack of leukocyte or monocyte/macrophage infi ltration in Fig. 1 . Plasma MPO and sL-selectin in humans and mice. A: Humans with SCD have increased plasma concentrations of MPO compared with apparently healthy humans (left bar graph, P < 0.05, n = 6). SCD mice also have increased plasma concentrations of MPO compared with the concentrations in AA mice (right bar graph, gray versus white bar). KYC was dissolved in PBS and administered by intraperitoneal or subcutaneous injection. KYC treatments had no effect on plasma MPO concentrations in AA (right bar graph, hatched versus white bar) or SCD mice (hatched and gray versus gray bar). Plasma MPO concentrations were increased in KYC-treated SCD mice compared with KYC-treated AA mice (right bar graph, hatched gray versus hatched bar, * P < 0.05, ** P < 0.01, n = 6). B: Humans with SCD have increased plasma sL-selectin levels than apparently healthy humans (left bar graph, ** P < 0.01, n = 6). SCD mice have increased plasma levels of sL-selectin compared with AA mice, which are reduced by KYC intraperitoneal or subcutaneous treatments (right bar graph, hatched gray versus hatched bar, *** P < 0.001, **** P < 0.0001, n = 6). Fig. I-A) , these data clearly demonstrate that KYC inhibits MPO-dependent oxidative stress. Data in Figs. 1-4 demonstrate that KYC is highly effective at inhibiting MPO-dependent oxidation of EC in vitro and in vivo, which begins to explain how this tripeptide is able to protect and improve vascular EC function even in environments characterized by high levels of MPO-dependent oxidative stress.
Many consider plasma ALT to be a biomarker of tissue injury and, more specifi cally, liver injury. SCD increased ALT concentrations by more than 6-fold over the concentrations in control AA mice ( Fig. 5 ) . Although KYC treatments tended to reduce ALT in SCD mice by more than 30%, the differences between the means were not of statistical signifi cance, even though a onetailed Student t -test yielded a P value of 0.07. Although these data are consistent with the idea that SCD induces liver injury, more sensitive and specifi c assays may be required to assess oxidative injury. To explore mechanisms mediating protection against oxidative injury, livers from SCD mice ± KYC treatments (0.3 mg/kg/day for 3 weeks via intraperitoneal or subcutaneous injection) were examined histologically and biochemically for changes in MPO, XO/XDH, 3-ClTyr, and 3-NO 2 Tyr. KYC treatments slightly increased immunoreactivity for MPO, slightly decreased 3-ClTyr, while markedly decreasing 3-NO 2 Tyr and increasing XO/XDH in SCD liver sections ( Fig. 6 ) . For a more quantitative assessment of protection, immunoblots for MPO, XO/XDH, 3-ClTyr, and 3-NO 2 Tyr were performed on liver homogenates. KYC treatments signifi cantly increased the expression of MPO and XO/XDH in SCD livers while To determine whether KYC protects EC against MPOdependent oxidation, we exposed EC cultures to MPO/ H 2 O 2 in the absence and presence of KYC. Fig. 4 shows that KYC (25 µM) reduced MPO-dependent chlorination of tyrosine in EC proteins compared with the levels in EC incubated with MPO/H 2 O 2 in the absence of KYC. As the anti-3-ClTyr antibody easily discriminates between low and high concentrations of 3-ClTyr (supplementary Fig. 2 . Effects of KYC on vascular MPO, 3-ClTyr, cell composition, and vessel structure . Representative images of MPO and 3-ClTyr immunofl uorescence (green) relative to nuclear staining for To-Pro3 (blue) in sections of thoracic aortas isolated from control AA and SCD mice; (A) anti-MPO, (B) anti-3-ClTyr, and (C) H&E stains of sections of thoracic aortas from control AA and SCD mice treated with either PBS or KYC (n = 6). Fig. 3 . Effects of KYC on vasodilatation . A: Acetylcholine (ACh)-induced relaxation responses for pressurized facialis arteries isolated from PBS-treated SCD mice (black squares) are impaired compared with those for arteries isolated from PBS-treated control AA mice (black triangles). KYC treatments (0.3 mg/kg/day via intraperitoneal or subcutaneous injections for 3 weeks) increased ACh-induced relaxation responses in arteries isolated from the SCD mice (inverted white triangles) to essentially the same levels as for arteries isolated from KYC-treated AA mice (white diamonds). B: ACh-induced relaxation responses for arteries isolated from KYC-treated AA mice (black triangles) tended to be slightly less than for arteries isolated from PBS-treated AA mice (black squares). However, the differences in the curves were not signifi cant (NS). Relaxation responses of arteries isolated from PBS-and KYC-treated AA mice (black squares and triangles, respectively) were inhibited by pretreatment with L-NAME (100 µM, white squares and triangles, respectively), confi rming that the mechanism of relaxation was eNOS-dependent. C: eNOS-dependent vasodilatation in arteries isolated from KYC-treated SCD mice (difference in area under the curves, black triangles minus white triangles) increased nearly 3-fold over levels in PBS-treated SCD mice (difference in area under the curves black squares minus white squares). These data demonstrate that KYC improves ACh-induced, EC-and eNOS-dependent vasodilatation in SCD mice (n = 17, ** P < 0.01, *** P < 0.005, **** P < 0.001). DISCUSSION Our fi ndings demonstrate that MPO plays a central role in the mechanisms by which SCD impairs vascular function. This conclusion is based on data showing that KYC decreases sL-selectin, a biomarker of leukocyte activation; decreases vascular levels of MPO and 3-ClTyr, a fi nger print biomarker of MPO activity; improves EC-and eNOSdependent vasodilatation; decreases plasma MDA levels; and protects EC from MPO-dependent oxidation. At the same time KYC prevents formation of 3-ClTyr and 3-NO 2 -Tyr formation in SCD liver while increasing liver MPO and XO/XDH levels, suggesting that KYC, by decreasing oxidative stress, reduces liver injury and enzymatic leakage from the livers of SCD mice.
sL-selectin studies demonstrate that KYC effectively inhibits leukocyte-vascular interactions in SCD mice. Immunofl uorescence studies demonstrate that KYC not only inhibits MPO binding and uptake by the vessel wall but also HOClmediated oxidative stress. Vasodilatation studies demonstrate that KYC dramatically improves endothelial-and eNOS-dependent vascular function in SCD mice. The fact that KYC inhibited 3-ClTyr formation in EC cultures treated reducing formation of 3-ClTyr and 3-NO 2 Tyr in SCD liver proteins ( Fig. 7 ) .
To determine whether inhibiting MPO decreased oxidative stress with respect to lipids, we measured plasma MDA in SCD mice treated with PBS or KYC. Fig. 8 shows that KYC treatments decreased plasma MDA levels in SCD mice. 5 . Effects of KYC on plasma ALT. KYC treatments (0.3 mg/kg/day via intraperitoneal or subcutaneous injections for 3 weeks) had little effect on plasma ALT concentrations in AA mice (hatched versus white bar). SCD mice had higher ALT than AA mice (gray versus white bar, ** P < 0.01 ). Although KYC treatments tended to decrease ALT in SCD mice (hatched gray versus gray bar), the differences between the means did not achieve statistical signifi cance ( P = 0.07). release MPO, which subsequently enters the vessel wall, increases infl ammation, and generates oxidants that impair vasodilatation ( 15, 16 ) . Interestingly, KYC decreased not only sL-selectin but also 3-ClTyr, a fi ngerprint biomarker of MPOdependent oxidative stress in the vessel wall of the SCD mice. In addition, immunofl uorescence data showed that MPO was taken up into the vessel wall. Possibly, MPO uptake by the vessel wall is also regulated in the same way as MPO is reported to regulate PMN activation and degranulation ( 17 ) . As sL-selectin and MPO are released from activated leukocytes by two separate mechanisms ( 10 ), our data suggest that KYC decreases leukocyte activation and interactions with the vessel wall but not necessarily degranulation. This result seems to run counter to the report suggesting that MPO enhances PMN activation and degranulation ( 17 ) . ELISA data in this initial study suggest that plasma MPO is not reduced in KYC-treated SCD mice. Possibly higher KYC concentrations are needed to decrease MPO in the SCD mice. Regardless, additional studies will be required to determine whether KYC treatments in SCD mice modulate the function of PMN, the most abundant cellular source of MPO. However, such studies are beyond the scope of the present article and will be pursued in a separate study.
KYC is a potent inhibitor of MPO activity. KYC decreases MPO-dependent HOCl production; LDL and protein oxidation; stimulated PMN-dependent MPO activity; and MPO-dependent EC injury and cell death ( 11 ) . Cell culture studies reveal KYC is not cytotoxic even when used at concentrations as high a 4 mM ( 11 ). Using LC/MS/MS to quantify plasma KYC, we observed that after subcutaneous injection, KYC followed a biphasic pattern of decay. In the early phase, in the fi rst 30 min, its plasma half-life was ‫ف‬ 10 min. In the late phase, after 1 h, its plasma half-life was ‫ف‬ 130 min (supplementary Fig. I-B) . KYC decreased ALT in SCD mice ( P = 0.07). This trend is consistent with other data showing that KYC protects SCD livers against MPO-dependent oxidative stress. Immunofl uorescence studies and immunoblot analyses confi rm that KYC increases MPO and XO/XDH expression in SCD livers and inhibits 3-ClTyr and 3-NO 2 Tyr formation in SCD liver proteins. Such increases in MPO and XO/XDH can be explained by the fact that healthy livers retain MPO and XDH more than injured livers and the fact that injured livers leak enzymes.
In conclusion, KYC, is an effective, nontoxic inhibitor of MPO activity ( 11 ) that decreases MPO-dependent oxidative stress with respect to plasma lipid peroxidation and oxidation of vascular tissues, improves vascular function, and decreases oxidative injury in SCD livers. Accordingly, KYC represents a new tool that may be useful for not only gaining a better understanding of the mechanisms by which MPO increases oxidative stress and impairs vascular function in SCD but also as a possible therapy for preventing MPO-dependent infl ammation and injury in SCD.
The authors thank Thomas Foster, Jianhai Du, Tongju Guan, and Weiling Wang for technical assistance, and Meghann Sytsma for assistance with the preparation of the manuscript. Fig. 8 . Effects of KYC on plasma MDA in SCD mice. The bar graph shows that KYC treatments (0.3 mg/kg/day via intraperitoneal and/or subcutaneous for 3 weeks) reduced plasma MDA levels in SCD mice (n = 6 per group, * P < 0.05). Plasma MDA levels in C57BL/6J mice were ‫ف‬ 1.2 µM (unpublished observations). with MPO and activated PMN provides additional support for the idea that KYC inhibits MPO-dependent oxidative stress to protect vascular EC function in SCD. The decrease in plasma ALT in KYC-treated SCD mice directly correlates with notable decreases in 3-ClTyr and 3-NO 2 Tyr in SCD liver homogenates, confi rming that KYC protects SCD livers against oxidative stress and injury.
Our fi ndings are consistent with observations by Freeman and associates who postulated that activated leukocytes Supplemental Material can be found at:
